Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/Sales ratio high or low?
The EV/Sales ratio of 1.23x is in line with its estimated 1-year average of 1.16x, near the high end of its estimated 1-year range (0.94x–1.34x).
As of 2026-10-06T21:34:07.387Z.
Calculation as of: 2026-10-06T21:34:07.387Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad03cc2eaddb42082332b148aee8d6851fa015397d59a0785f41cacae5aa3ea4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
1.23x
EV/SALES RATIO AVG TTM
N/A
EV/SALES RATIO AVG 3Y
N/A
EV/SALES RATIO AVG 5Y
N/A
EV/SALES RATIO AVG 10Y
N/A
EV/SALES RATIO AVG 15Y
N/A
EV/SALES RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
4.38x
median of 549 covered companies
CURRENT VS SECTOR MEDIAN
-71.92%
vs the sector median at left
Market Cap
$656.59M
EV/Sales Ratio
6.80x
TTM Avg
3080.33x
3Y Avg
3087.28x
5Y Avg
1898.38x
Market Cap
$673.41M
EV/Sales Ratio
1.52x
TTM Avg
1.59x
3Y Avg
2.50x
5Y Avg
2.28x
Market Cap
$681.27M
EV/Sales Ratio
N/A
TTM Avg
2.20x
3Y Avg
6.98x
5Y Avg
6.98x
Market Cap
$634.30M
EV/Sales Ratio
3.60x
TTM Avg
5.69x
3Y Avg
10.23x
5Y Avg
9.87x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Starling Oncology, Inc. (STLN) | $657.89M | 1.23x | N/A | N/A | N/A |
| 4D Molecular Therapeutics, Inc. (FDMT)vs › | $656.59M | 6.80x | 3080.33x | 3087.28x | 1898.38x |
| Annexon, Inc. (ANNX)vs › | $660.29M | N/A | N/A | N/A | N/A |
| Helus Pharma Inc. (HELP)vs › | $666.95M | N/A | N/A | N/A | N/A |
| MiMedx Group, Inc. (MDXG)vs › | $673.41M | 1.52x | 1.59x | 2.50x | 2.28x |
| Aura Biosciences, Inc. (AURA)vs › | $638.20M | N/A | N/A | N/A | N/A |
| Verastem, Inc. (VSTM)vs › | $681.02M | 7.19x | 41.09x | 46.52x | 55.30x |
| Solid Biosciences Inc. (SLDB)vs › | $681.27M | N/A | 2.20x | 6.98x | 6.98x |
| Zevra Therapeutics, Inc. (ZVRA)vs › | $634.30M | 3.60x | 5.69x | 10.23x | 9.87x |
| Prime Medicine, Inc. (PRME)vs › | $632.16M | 171.17x | 136.19x | 307.18x | 307.18x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/SALES RATIO |
|---|---|
| 2026-10-05 | 1.21x |
| 2026-10-02 | 1.22x |
| 2026-10-01 | 1.20x |
| 2026-09-30 | 1.22x |
| 2026-09-29 | 1.25x |
| 2026-09-28 | 1.27x |
| 2026-09-25 | 1.28x |
| 2026-09-24 | 1.25x |
| 2026-09-23 | 1.30x |
| 2026-09-22 | 1.34x |
| 2026-09-21 | 1.31x |
| 2026-09-18 | 1.33x |
| 2026-09-17 | 1.27x |
| 2026-09-16 | 1.25x |
| 2026-09-15 | 1.23x |
| 2026-09-14 | 1.25x |
| 2026-09-11 | 1.19x |
| 2026-09-10 | 1.20x |
| 2026-09-09 | 1.21x |
| 2026-09-08 | 1.22x |
| 2026-09-04 | 1.15x |
| 2026-09-03 | 1.16x |
| 2026-09-02 | 1.18x |
| 2026-09-01 | 1.15x |
| 2026-08-31 | 1.14x |
| 2026-08-28 | 1.19x |
| 2026-08-27 | 1.22x |
| 2026-08-26 | 1.26x |
| 2026-08-25 | 1.21x |
| 2026-08-24 | 1.18x |
| 2026-08-21 | 1.24x |
| 2026-08-20 | 1.26x |
| 2026-08-19 | 1.28x |
| 2026-08-18 | 1.23x |
| 2026-08-17 | 1.22x |
| 2026-08-14 | 1.24x |
| 2026-08-13 | 1.21x |
| 2026-08-12 | 1.22x |
| 2026-08-11 | 1.20x |
| 2026-08-10 | 1.19x |
| 2026-08-07 | 1.23x |
| 2026-08-06 | 0.98x |
| 2026-08-05 | 0.99x |
| 2026-08-04 | 1.02x |
| 2026-08-03 | 1.01x |
| 2026-07-31 | 0.96x |
| 2026-07-30 | 1.00x |
| 2026-07-29 | 0.94x |
| 2026-07-28 | 0.98x |
| 2026-07-27 | 1.02x |
| 2026-07-24 | 0.98x |
| 2026-07-23 | 1.00x |
| 2026-07-22 | 1.04x |
| 2026-07-21 | 1.06x |
| 2026-07-20 | 1.07x |
| 2026-07-17 | 1.05x |
| 2026-07-16 | 1.03x |
| 2026-07-15 | 1.10x |
| 2026-07-14 | 1.21x |
| 2026-07-13 | 1.20x |
| 2026-07-10 | 1.14x |
| 2026-07-09 | 1.13x |
| 2026-07-08 | 1.10x |
| 2026-07-07 | 1.13x |
